Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Pseudomyxoma Peritonei 2Pain, Postoperative 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

Mitomycin 3Surveys and Questionnaires 2Hyperthermic Intraperitoneal Chemotherapy 2Capecitabine 2Bromelains 2Acetylcysteine 2tislelizumab 1molgramostim 1irinotecan sucrosofate 1cryoprecipitate coagulum 1Tacrolimus 1Standard of Care 1Specimen Handling 1Sirolimus 1Referral and Consultation 1Radiosurgery 1Psychiatric Rehabilitation 1Pharmacogenomic Testing 1Oxaliplatin 1Nivolumab 1Methods 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lansoprazole 1Ipilimumab 1Gemcitabine 1Fluorouracil 1Floxuridine 1Early Intervention, Educational 1Cytoreduction Surgical Procedures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pseudomyxoma Peritonei × Bromelains × Clear all
NCT04982146 2022-06-02

Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Maimónides Biomedical Research Institute of Córdoba

Phase 1 Unknown
10 enrolled

Pseudomyxoma Peritonei

NCT03976973 2022-03-15

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Mucpharm Pty Ltd

Phase 2 Unknown
62 enrolled

Adenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Neoplasms, Cystic, Mucinous, and Serous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡